Luke Miels inherited the GSK CEO role as the company posted what he called strong performance last year. (GSK) In his first investor update as GSK’s CEO, Luke Miels defined a core of his vision for ...
In Luke Miels' first quarter as CEO, GSK's Q1 revenue of £7.6 billion marked a 5% increase year over year at constant exchange rates. (GSK) In GSK’s first quarter under Luke Miels as CEO, the ...
Hosted on MSN
GSK steps up cancer fight as new boss Luke Miels signals a change of direction: Alex Brummer
The impact of regime change at GSK is finally being seen. The Emma Walmsley period focused on sorting out the structure of the enterprise, selling off consumer healthcare to focus on core R&D, ...
GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Half a year into taking ...
When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets. Miels—who served as GSK’s ...
LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker will aim to lift sales growth and speed up work on new medicines in its next phase of growth through a sharper ...
Emma Walmsley has served as CEO of GlaxoSmithKline since 2017. From the Philadelphia Business Journal. GSK is making a change at the top. The London-based Big Pharma company, which has major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results